8-K current report · filed Sep 23, 2026

Corcept Therapeutics Inc (CORT) 8-K Current Report: September 23, 2026

Item 5.02Item 7.01Item EX-99.1CORT overview

Short answer

Corcept Therapeutics Inc (CORT) filed an 8-K current report with the SEC on September 23, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). President of Corcept Endocrinology Sean Maduck resigns effective October 1, 2026.

Corcept Therapeutics Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • President of Corcept Endocrinology Sean Maduck resigns effective October 1, 2026
  • No disagreement cited with operations, financial statements, policies or practices
  • Consulting agreement runs through September 30, 2027, unless terminated earlier
  • Monthly consulting fee of $57,000, with 30 days’ termination notice
  • Outstanding stock options continue vesting during the consulting term

Item 7.01 · Regulation FD Disclosure

  • CEO transition announced: Justin Gunn succeeds retiring Mr. Maduck
  • Leadership change creates execution and strategy continuity considerations
  • Exhibit 99.1 contains the company’s detailed transition announcement

Item EX-99.1 · Exhibit EX-99.1

  • Sean Maduck retiring as Endocrinology president after 14 years, remaining as senior commercial advisor
  • Justin Gunn assumes Endocrinology leadership October 1 and joins Executive Team, reporting to CEO Joseph Belanoff
  • Leadership change places commercial executive with oncology launch experience over Cushing’s syndrome business
  • Transition comes as Corcept targets broader awareness and treatment reach in Cushing’s syndrome

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Corcept Therapeutics Inc 8-K filings

Get the next CORT 8-K as it lands

Follow CORT for push alerts, or ask the research agent what this filing means.